Emergence of Chemotherapy Related Hyperglycemia in nOn-diabetic Patients

N/AUnknownNCT03062072

National Cancer Center, Korea300 enrolled

Overview

To assess chemotherapy related hyperglycemia in non-diabetic patients, the investigators will assess the incidence of hyperglycemia and analyze co-medications and risk factors.

Study Type

OBSERVATIONAL

Enrollment

300

Conditions

Cancer Colon Cancer Breast Cancer Malignant Lymphoma

Interventions

ChemotherapyDRUG

Chemotherapy containing glucocorticoid as anti-emetics or anti-cancer agent except for targeted agents

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with cancers (colorectal, breast) who treated with curative intents and ones with malignant lymphoma who are expected to achieve complete remission with chemotherapy (mainly, CHOP regimen) * Patients without history of diabetes mellitus * Normal glucose tolerance, as defined in the protocol Exclusion Criteria: * Patients with diabetes mellitus or hyperglycemia, as defined in the protocol

Locations (2)

National Cancer Center, Korea

Goyang, South Korea

RECRUITING

Seoul National University Boramae Medical Center

Seoul, South Korea

RECRUITING

Outcomes

Primary Outcomes

Incidence of type 2 diabetes mellitus

Percentage of patients who progressed to type 2 diabetes

Time frame: during chemotherapy (about 1 year)

Secondary Outcomes

Change in HbA1c

Time frame: during chemotherapy (about 1 year)

Change in glycated albumin

Time frame: during chemotherapy (about 1 year)

Recurrence free survival (RFS)

Time frame: from the Date of enrollment to the date of disease recurrence or date of any cause assessed upto 100 months

Central Contacts

Su Jeong Go

CONTACT

+82-31-920-2364 sjgo@ncc.re.kr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.